<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02543099</url>
  </required_header>
  <id_info>
    <org_study_id>20150811</org_study_id>
    <nct_id>NCT02543099</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Policosanol</brief_title>
  <official_title>The Effect of Policosanol on Elderly Patients With Endothelial Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Chinese Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General Hospital of Chinese Armed Police Forces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical efficacy and safety of policosanol on
      elderly patients with endothelial dysfunction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 selected elderly patients with endothelial dysfunction were randomized to two
      groups,Group1:received policosanol 20mg qd;Group2:received placebo 20mg qd；endothelial
      function was tested by peripheral arterial tonometry(PAT) before and after 6 months'
      treatment with policosanol or placebo respectively; Endothelial dysfunction is defined as
      reactive hyperemia index(RHI)&lt; 1.67; The aim of this study is to assess the clinical efficacy
      and safety of policosanol on elderly patients with endothelial dysfunction.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reactive hyperemia index (RHI) measured by Endo-PAT</measure>
    <time_frame>6 months after the treatment with policosanol or placebo</time_frame>
    <description>Novel digital pulse amplitude tonometry (PAT) offers the possibility of an easy and rapid assessment of vascular function. Endothelial function was assessed using a Endo-PAT device (Itamar Medical Ltd, Caesarea, Israel)and recorded as a reactive hyperemia index (RHI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of Policosanol in Older Patients</measure>
    <time_frame>6 months after the treatment with policosanol or placebo</time_frame>
    <description>Triglyceride(TG),total cholesterol (TC), low-density lipoprotein(LDL-C), high- density lipoprotein cholesterol (HDL-C ), lipoprotein (a), apolipoprotein AI (apo AI) and apolipoprotein B (apo B) were measured at the clinical biochemistry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the safety of policosanol evaluated by clinical and statistical analysis, including clinical adverse reactions, laboratory indexes (such as liver function, kidney function and creatine kinase (CK) value) and vital signs</measure>
    <time_frame>6 months after the treatment with policosanol or placebo</time_frame>
    <description>The safety was evaluated by clinical and statistical analysis, including clinical adverse reactions, laboratory indexes (such as liver function, kidney function and creatine kinase (CK) value) and vital signs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>policosanol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive policosanol 20mg daily until the end of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo 20mg daily until the end of the trial;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>policosanol</intervention_name>
    <description>Patients will receive policosanol 20mg Qd</description>
    <arm_group_label>policosanol</arm_group_label>
    <other_name>PPG</other_name>
    <other_name>Lipex</other_name>
    <other_name>dupla</other_name>
    <other_name>ateromixol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will receive placebo 20mg Qd;</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age over 60 years old；

          2. Patients with endothelial dysfunction

          3. Provision of informed consent prior to any study specific procedures.

        Exclusion Criteria:

          1. Acute myocardial infarction ,severe trauma , major operation or stroke within six
             months;

          2. Tumor or inflammatory diseases

          3. Known allergies to policosanol

          4. Life expectancy less than 1 year

          5. secondary dyslipidemia 6.taking other experimental medicine within six months;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ping ye, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of geriatric Cardiology, Chinese PLA general hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ping ye, M.D</last_name>
    <phone>86-10-57976872</phone>
    <email>dodyy0601@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yuanyuan duan, M.M</last_name>
    <phone>86-10-57976873</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of South, General Hospital of Chinese People's Armed Police Forces</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yuanyuan duan, M.M..</last_name>
      <phone>86-10-57976873</phone>
      <email>dodyy0601@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Reriani MK, Lerman LO, Lerman A. Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med. 2010 Jun;4(3):351-60. doi: 10.2217/bmm.10.61. Review.</citation>
    <PMID>20550469</PMID>
  </results_reference>
  <results_reference>
    <citation>Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis. 2010 Nov;20(9):656-61. doi: 10.1016/j.numecd.2009.05.017. Epub 2009 Aug 20.</citation>
    <PMID>19699071</PMID>
  </results_reference>
  <results_reference>
    <citation>Faizi AK, Kornmo DW, Agewall S. Evaluation of endothelial function using finger plethysmography. Clin Physiol Funct Imaging. 2009 Sep;29(5):372-5. doi: 10.1111/j.1475-097X.2009.00882.x. Epub 2009 Jun 22.</citation>
    <PMID>19552735</PMID>
  </results_reference>
  <results_reference>
    <citation>Noa M, Más R, Lariot C. Protective effect of policosanol on endothelium and intimal thickness induced by forceps in rabbits. J Med Food. 2007 Sep;10(3):452-9.</citation>
    <PMID>17887938</PMID>
  </results_reference>
  <results_reference>
    <citation>Moerland M, Kales AJ, Schrier L, van Dongen MG, Bradnock D, Burggraaf J. Evaluation of the EndoPAT as a Tool to Assess Endothelial Function. Int J Vasc Med. 2012;2012:904141. doi: 10.1155/2012/904141. Epub 2012 Feb 14.</citation>
    <PMID>22500237</PMID>
  </results_reference>
  <results_reference>
    <citation>Vizzardi E, Gavazzoni M, Della Pina P, Bonadei I, Regazzoni V, Sciatti E, Trichaki E, Raddino R, Metra M. Noninvasive assessment of endothelial function: the classic methods and the new peripheral arterial tonometry. J Investig Med. 2014 Aug;62(6):856-64. doi: 10.1097/JIM.0000000000000096. Review.</citation>
    <PMID>24945081</PMID>
  </results_reference>
  <results_reference>
    <citation>Onkelinx S, Cornelissen V, Goetschalckx K, Thomaes T, Verhamme P, Vanhees L. Reproducibility of different methods to measure the endothelial function. Vasc Med. 2012 Apr;17(2):79-84. doi: 10.1177/1358863X12436708. Epub 2012 Mar 8.</citation>
    <PMID>22402933</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2015</study_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>policosanol</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Policosanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

